LONDON, UK: Apogee Therapeutics LLC has accomplished $149 million Series B financing round. RTW Venture Fund, alongside different funding vehicles of RTW Investments LP participated within the Series B financing spherical along with different investors.
Apogee Therapeutics is a privately held pre-clinical stage biotech advancing potentially best-in-class therapies for immunological and inflammatory disorders. The firm is constructing a pipeline of product candidates targeting clinically validated biology and well-established development pathways.
Through a strategic partnership with Paragon Therapeutics, Apogee has the choice for unique development and commercial rights to a suite of antibodies which have been particularly engineered to focus on immunological and inflammatory disorders. Its lead program, APG777, is anticipated to enter clinical trials in 2023.
Joshua Kennedy-Smith, PhD, Managing Director on the Investment Manager, will take part in conferences of Apogee’s board of administrators in an observer capacity. He said:
“We are excited to co-lead Apogee’s Series B financing and to support its efforts to develop potentially best-in-class immunological therapies. The addition of Apogee to RTW Venture Fund’s portfolio additional expands our focus on inflammatory illness with excessive unmet want and investing in innovative therapeutic modalities.”
The Investment Manager is looking ahead to rising the Company’s funding pipeline and updating shareholders on additional investments by the Company in due course.